322 related articles for article (PubMed ID: 24124374)
21. Similar eicosapentaenoic acid and docosahexaenoic acid plasma levels achieved with fish oil or krill oil in a randomized double-blind four-week bioavailability study.
Yurko-Mauro K; Kralovec J; Bailey-Hall E; Smeberg V; Stark JG; Salem N
Lipids Health Dis; 2015 Sep; 14():99. PubMed ID: 26328782
[TBL] [Abstract][Full Text] [Related]
22. In vitro dissolution behaviour and absorption in humans of a novel mixed l-lysine salt formulation of EPA and DHA.
Manusama K; Balvers M; Diepeveen-de Bruin M; Headley L; Bosi R; Schwarm M; Witkamp R
Prostaglandins Leukot Essent Fatty Acids; 2021 Jan; 164():102232. PubMed ID: 33360684
[TBL] [Abstract][Full Text] [Related]
23. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
[TBL] [Abstract][Full Text] [Related]
24. Bioavailability of marine n-3 fatty acid formulations.
Dyerberg J; Madsen P; Møller JM; Aardestrup I; Schmidt EB
Prostaglandins Leukot Essent Fatty Acids; 2010 Sep; 83(3):137-41. PubMed ID: 20638827
[TBL] [Abstract][Full Text] [Related]
25. Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids.
Rupp H; Wagner D; Rupp T; Schulte LM; Maisch B
Herz; 2004 Nov; 29(7):673-85. PubMed ID: 15580322
[TBL] [Abstract][Full Text] [Related]
26. Short term effects of different omega-3 fatty acid formulation on lipid metabolism in mice fed high or low fat diet.
Tang X; Li ZJ; Xu J; Xue Y; Li JZ; Wang JF; Yanagita T; Xue CH; Wang YM
Lipids Health Dis; 2012 Jul; 11():70. PubMed ID: 22676394
[TBL] [Abstract][Full Text] [Related]
27. Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia.
Davidson MH; Phillips AK; Kling D; Maki KC
Expert Rev Cardiovasc Ther; 2014 Sep; 12(9):1045-54. PubMed ID: 25089906
[TBL] [Abstract][Full Text] [Related]
28. Strategies to improve bioavailability of omega-3 fatty acids from ethyl ester concentrates.
Maki KC; Dicklin MR
Curr Opin Clin Nutr Metab Care; 2019 Mar; 22(2):116-123. PubMed ID: 30550388
[TBL] [Abstract][Full Text] [Related]
29. Bioavailability of long chain omega-3 polyunsaturated fatty acids from phospholipid-rich herring roe oil in men and women with mildly elevated triacylglycerols.
Cook CM; Hallaråker H; Sæbø PC; Innis SM; Kelley KM; Sanoshy KD; Berger A; Maki KC
Prostaglandins Leukot Essent Fatty Acids; 2016 Aug; 111():17-24. PubMed ID: 27151222
[TBL] [Abstract][Full Text] [Related]
30. Bioavailability of long-chain n-3 fatty acids from enriched meals and from microencapsulated powder.
Hinriksdottir HH; Jonsdottir VL; Sveinsdottir K; Martinsdottir E; Ramel A
Eur J Clin Nutr; 2015 Mar; 69(3):344-8. PubMed ID: 25406967
[TBL] [Abstract][Full Text] [Related]
31. ω-3 carboxylic acids for hypertriglyceridemia.
Roth EM
Expert Opin Pharmacother; 2015 Jan; 16(1):123-33. PubMed ID: 25480558
[TBL] [Abstract][Full Text] [Related]
32. A self-emulsifying Omega-3 ethyl ester formulation (AquaCelle) significantly improves eicosapentaenoic and docosahexaenoic acid bioavailability in healthy adults.
Bremmell KE; Briskey D; Meola TR; Mallard A; Prestidge CA; Rao A
Eur J Nutr; 2020 Sep; 59(6):2729-2737. PubMed ID: 31637467
[TBL] [Abstract][Full Text] [Related]
33. Wax Ester Rich Oil From The Marine Crustacean, Calanus finmarchicus, is a Bioavailable Source of EPA and DHA for Human Consumption.
Cook CM; Larsen TS; Derrig LD; Kelly KM; Tande KS
Lipids; 2016 Oct; 51(10):1137-1144. PubMed ID: 27604086
[TBL] [Abstract][Full Text] [Related]
34. Bioequivalence Demonstration for Ω-3 Acid Ethyl Ester Formulations: Rationale for Modification of Current Guidance.
Maki KC; Johns C; Harris WS; Puder M; Freedman SD; Thorsteinsson T; Daak A; Rabinowicz AL; Sancilio FD
Clin Ther; 2017 Mar; 39(3):652-658. PubMed ID: 28189365
[TBL] [Abstract][Full Text] [Related]
35. Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations--a comparative bioavailability study of fish oil vs. krill oil.
Schuchardt JP; Schneider I; Meyer H; Neubronner J; von Schacky C; Hahn A
Lipids Health Dis; 2011 Aug; 10():145. PubMed ID: 21854650
[TBL] [Abstract][Full Text] [Related]
36. Lymphatic transport of eicosapentaenoic and docosahexaenoic acids as triglyceride, ethyl ester and free acid, and their effect on cholesterol transport in rats.
Ikeda I; Imasato Y; Nagao H; Sasaki E; Sugano M; Imaizumi K; Yazawa K
Life Sci; 1993; 52(16):1371-9. PubMed ID: 8464336
[TBL] [Abstract][Full Text] [Related]
37. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
McKenney JM; Sica D
Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
[TBL] [Abstract][Full Text] [Related]
38. Distribution, interconversion, and dose response of n-3 fatty acids in humans.
Arterburn LM; Hall EB; Oken H
Am J Clin Nutr; 2006 Jun; 83(6 Suppl):1467S-1476S. PubMed ID: 16841856
[TBL] [Abstract][Full Text] [Related]
39. Lipid effects of switching from prescription EPA+DHA (omega-3-acid ethyl esters) to prescription EPA only (icosapent ethyl) in dyslipidemic patients.
Crandell JR; Tartaglia C; Tartaglia J
Postgrad Med; 2016 Nov; 128(8):859-864. PubMed ID: 27684412
[TBL] [Abstract][Full Text] [Related]
40. Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.
Weintraub HS
Postgrad Med; 2014 Nov; 126(7):7-18. PubMed ID: 25387209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
